US trial for anti-infective catheters:
This article was originally published in Clinica
Executive Summary
Implemed is to begin a US clinical trial of its Oligon antimicrobial polymer-coated urinary catheters after receiving an investigational device exemption from the FDA. Researchers will assess how well the Oligon technology reduces device-associated infections that frequently occur in the large bore catheters used in the urinary tract. The technology is based on oligodynamic iontopheresis, whereby silver ions are released to destroy microbes on the surface of a device. The multicentre trial will involve over 600 patients and be completed by the end of the year, said the Watertown, Massachusetts-based company.